FATLOSE trial: Fecal Administration To LOSE weight.

Recent research shows that obesity is associated with changed bowel flora composition with a relative abundance of the two dominant bacterial divisions, the Bacteroidetes and the Firmicutes. Interestingly, this specific bacteria associated condition is transmissible: colonization of obese mice with an ‘leanmicrobiota’ results in a significantly greater decrease in total body fat than colonization with a ‘obese microbiota. In addition, Bacteroidetes species are decreased and Firmicutes increased in feces of obese people compared to lean people. Moreover weight correlated with percentage loss of body weight in obese subjects. Changing fecal flora composition in overweight MS patients might therefore be total novel and effective prevention of the rapid increase patients with type 2 diabetes, that is needed so urgently.
This trial is performed which infusion of lean donor feces through a duodenal tube, compared with autologic (patients own feces) transplantation.
Endpoints are changes in faecal flora, weight, insulin resistance and systhemic/biochemical parameters.
Folluw up is 12 weeks

Hypothesis: infusion of lean donor feces in obese subjects is effective on weight reduction, systemic inflammatory pathways and insulin resistance.

1. Baseline;

2. 2days;

3. 2 weeks;

4. 6 weeks;

5. 12 weeks.

1. Arm 1: allogenic fecal therapy
(donor feces from lean volunteer);

2. Arm 2: autologic fecal therapy
(patients' own feces).